Dupilumab-treatment for uncontrolled CRSwNP: real-life 15-months follow-up data

Mathias Heidemann,Robert Böscke, Marius Thalau,Stephanie Jeschke, Karl-Ludwig Bruchhage

Abstract- und Posterband - 93. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn Interface - Fokus Mensch im Zeitalter der technisierten MedizinLaryngo-Rhino-Otologie（2022）

引用 0|浏览0

暂无评分

摘要

Background Dupilumab was the first biological drug to be approved for the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Objective: To evaluate the effectiveness and safety of Dupilumab-treatment for uncontrolled CRSwNP in a real-life setting.

查看译文

关键词

uncontrolled crswnp,dupilumab-treatment,real-life

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要